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Abstract
Background: Preeclampsia (PE) is the first worldwide cause of death in pregnant women, intra-uterine growth
retardation, and fetal prematurity. Some vascular endothelial grown factor gene (VEGF) polymorphisms have been
associated to PE and other pregnancy disturbances. We evaluated the associations between VEGF genotypes/
haplotypes and PE in Mexican women.
Methods: 164 pregnant women were enrolled in a case-control study (78 cases and 86 normotensive pregnant
controls). The rs699947 (-2578C/A), rs1570360 (-1154G/A), rs2010963 (+405G/C), and rs25648 (-7C/T), VEGF variants
were discriminated using Polymerase Chain Reaction - Restriction Fragment Length Polymorphism (PCR-RFLP)
methods or Taqman single nucleotide polymorphism (SNP) assays.
Results: The proportions of the minor allele for rs699947, rs1570360, rs2010963, and rs25648 VEGF SNPs were 0.33,
0.2, 0.39, and 0.17 in controls, and 0.39, 0.23, 0.41, and 0.15 in cases, respectively (P values > 0.05). The most
frequent haplotypes of rs699947, rs1570360, rs2010963, and rs25648 VEGF SNPs, were C-G-C-C and C-G-G-C with
frequencies of 0.39, 0.21 in cases and 0.37, 0.25 in controls, respectively (P values > 0.05)
Conclusion: There was no evidence of an association between VEGF alleles, genotypes, or haplotypes frequencies
and PE in our study.
Background
Pre-eclampsia (PE) is a multi-organ disorder defined as
elevated blood pressure (>140/90 mmHg) and protei-
nuria that may develop from 20 weeks gestation. PE is
the first cause of maternal death in the western world
and affects 5 to 8% of pregnant women, depending on
the studied population and definitions of PE [1-3]. The
Mexican Secretary of Health Registry reported 278
deaths by PE in 2007 in the country [4].
The etiopathology of PE remains unknown, but
improper placentation has been suggested as a possible
etiologic factor. This process involves the abnormal
infiltration of the cytotrophoblast into the decidual
endometrium and development of the spiral arteries
originated from the myometrium. As a result, the dia-
meter of the spiral arteries enlarge while arteries lose
elasticity to allow an increased demand of blood flow to
satisfy the intensifying demands of the growing fetus.
Improper cytotrophoblast invasion may affect vascular
remodelling and blood supply to the fetus, leading to
local placental hypoxia [5-7]. Expression of vascular
endothelial growth factor (VEGF) has been implied as a
hypoxia-induced factor possibly associated to PE, as has
been suggested previously [8]. Gu et al. observed
increased mRNA and protein levels of VEGF in response
to hypoxia in cultured cytotrophoblasts [9]. Zhou et al.
found that cytotrophoblast differentiation and invasion
during pregnancy is regulated through the VEGF recep-
tor-2. They also found that VEGF regulates cytotropho-
blast survival and that expression is deregulated in severe
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between some VEGF polymorphisms and PE in selected
populations, with some discrepancies [3,11-14]. No asso-
ciation studies for gene polymorphisms and PE have
been reported for the Mexican population, despite the
prevalence of this pregnancy disorder in the region. The
purpose of the present study was to analyze the associa-
tion of rs699947 (-2578C/A), rs1570360 (-1154G/A),
rs2010963 (+405G/C), and rs25648 (-7C/T) VEGF poly-
morphisms in a sample of Mexican pregnant women
enrolled during 2009-2010.
Methods
Patients and samples collection
This study was approved by the Institutional Review
Board of the Unidad Medica de Alta Especialidad
( U M A E )#2 3o ft h eI n s t i t u t oM e x i c a n od e lS e g u r o
Social (IMSS) in Monterrey, Mexico. One hundred
sixty-four unrelated pregnant women (86 PE cases and
78 normotensive controls), who provided written
informed consent for their participation, were enrolled
from the High Risk Pregnancy Outpatient Service of the
UMAE # 23 between September 2009 and April 2010.
Women between 15-38 years old with singleton preg-
nancy, 16-38 gestation weeks (GW), who lived in the
metropolitan area of Monterrey, were eligible to partici-
pate. The PE diagnosis was made according to the
guidelines of the International Society for the Study of
Hypertension in Pregnancy [15]. In general, these guide-
lines include two recordings of diastolic blood pressure
of 90 mmHg at least 4 h apart in previously normoten-
sive women and proteinuria of 300 mg or more in 24 h,
or two readings of at least ++ on dipstick analyses. PE
was considered severe if blood pressure of 160 mm Hg
systolic or higher or 110 mm Hg diastolic or higher on
two occasions at least 6 hours apart while the patient
was on bed rest, and proteinuria of 5 g or higher in a
24-hour urine specimen or 3+ or greater in two random
urine samples collected at least 4 hours apart were pre-
sent [16]. Exclusion criteria included multiple pregnan-
cies, pregnancies with structural or chromosomic fetus
malformations detected by ultrasound, chronic hyper-
tension, chronic renal disease, gestational diabetes melli-
tus, and underlying medical diseases such as rheumatoid
arthritis, and systemic lupus erythematosus.
A questionnaire, consisting of demographic and gyne-
cologic data and risk factors (including family history of
PE, cardiovascular disease, type 2 diabetes mellitus or
autoimmune diseases) was administered to each patient
by the participant gynecologist, and a venous blood
sample was obtained using EDTA collection tubes.
Blood samples were maintained at 4°C until their
processing.
SNP selection
Criteria for SNP selection included: SNPs for which an
association with PE has been reported in other popula-
tions, and considering the potential impact on gene
expression only SNPs located in promoter region of
VEGF gene or inside its 5’UTR were considered.
According to these criteria, rs699947 and rs1570360 var-
iants (located in the VEGF promoter), and rs2010963
and rs25648 (located in 5’UTR of the VEGF gene) were
included. Relative to translation start site, the variants
rs699947 and rs1570360 are known as -2578C/A and
-1154G/A, respectively [17,18]; while the rs2010963 SNP
is called +405G/C (according to mRNA position) or
-634G/C (relative to translation start site). In the same
sense, rs25648 alternative names are 534C/T and -7C/T
respectively.
Nucleic acid extraction and genotyping
DNA was isolated from 1 mL of blood sample using a
standard fenol/chloroform method coupled to ethanol
precipitation. Table 1 shows a summary of the genotyp-
ing methods employed for the variants screening. PCR
coupled to Restriction Fragment Length Polymorphism
(PCR-RFLP) method was used to discriminate the
rs699947, rs1570360, and rs2010963 VEGF polymorphic
variants, respectively. We used the protocols described
by Banyasz I et al (rs699947 and rs2010963) [3] and Liu
Q et al. (rs1570360) [19], respectively. Some modifica-
tions in the primer sequences were included; these mod-
ifications are indicated in bold letters in Table 1. All the
PCR reactions were made in a volume of 10 μlc o n t a i n -
ing 100 ng of genomic DNA, 0.5 μM of each primer,
and 1× of GoTaq Colorless Master Mix (Promega:
Madison, WI). PCR cycling conditions were as follows:
94°C for 5 min; 35 cycles of 94°C for 30 s, 60°C of
annealing temperature for 30 s, and 72°C for 30 s; a
final extension step of 72°C for 5 min was included.
PCR products were digested with Bgl II (rs699947),
Mnl I (rs1570360), and BsmF I (rs2010963) at 37°C
(rs699947 and rs1570360) or at 65°C (rs2010963) over-
night, respectively. The rs699947 and rs2010963
digested products were electrophoresed through 3.5%
agarose gels and visualized by ethidium bromide stain-
ing. Digested products of rs1570360 VEGF variant were
visualized using the DNA 1000 LabChip kit on the Agi-
lent 2100 Bioanalyzer (Agilent: Palo Alto, CA). Length
of PCR and PCR-RFLPs products are shown in Table 1.
The evaluation of the rs25648 VEGF variant was
performed using a predesigned 5’-nuclease assay with
TaqMan MGB probes (Applied Biosystems: Foster City,
CA). All reactions were performed in 10 μLo fv o l u m e
and 10 ng of genomic DNA. Standard PCR cycling
conditions were used and the allelic discrimination was
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StepOne v2.0 software (Applied Biosystems).
All the SNPs were validated by direct sequencing of
PCR products obtained from four patients using BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems), and analyzed in an Avant 3100 Genetic Analyzer.
To ensure reliability of the results, duplicate samples
and known genotyped samples were included in the
analysis as quality controls.
Data Analysis
General variables of the study groups such as maternal
age, gestational age, and number of pregnancies, were
compared using the Student’s t test. In the control
group, SNPs genotypes were tested for departures from
Hardy-Weinberg equilibrium by exact test. To compare
known risk factors, allele, and genotype frequencies
between the study groups, a chi-square test was per-
formed. Linkage disequilibrium statistics and haplotypes
analysis, including haplotypes frequency estimation, as
well as an analysis of association between haplotypes
and PE, were made using SNPStats software http://
bioinfo.iconcologia.net/index.php?module=Snpstats. The
Odds Ratio (OR) values were calculated for each allele,
genotype, and haplotype. For the adjustment of gesta-
tional age, logistic regression analysis was used to com-
pare allele and genotype frequencies between PE and
the control group. Study power was calculated at the
end of the study using Quanto software v1.2.4 [20]. For
each SNP we considered its minor allele frequency as
reported in the Mexican HapMap project. Depending
on the SNP, in the analysis an effect of size 2 or greater
was established.
The level of significance was set at P < 0.05. Statistical
analysis was performed using Sigma Plot software v11.
Results
One hundred and sixty four unrelated pregnant women
(86 PE cases and 78 normotensive controls) were
included in the study. The comparison among the
general variables of the study population (Table 2)
showed that gestational age was the only variable asso-
ciated to PE (P = 0.028). We did not find an association
between known risk factors and PE (P > 0.05). Genotype
frequencies for all the SNPs included in the study were
in Hardy-Weinberg equilibrium in the controls (P >
0.05). Table 3 displays the genotypes and minor allele
frequencies for each SNP in cases and controls. The
proportions for the minor allele for rs699947,
rs1570360, rs2010963, and rs25648 VEGF SNPs were
0.33, 0.2, 0.39, and 0.17 in controls, and 0.39, 0.23, 0.41,
and 0.15 in cases, respectively (Table 3). We did not
observe significant differences between individual geno-
types or allele frequencies of the studied VEGF SNPs in
the cases and control groups (P values > 0.05).
In a statistical approximation, an association between
genotype/allele frequencies and severity of the disease
was not found (table S1 of Additional file 1). To test the
association between PE onset and VEGF genotype var-
iants, the group of severe PE patients was classified in
early and late PE, with a cut off at 35 GW. Again, no
association between VEGF genotypes and PE onset was
found (P values > 0.05; data not shown).
Table 1 Genotyping methods description
SNP ID Primer sequences* Genotyping method
(restriction endonuclease)
PCR- RFLP products length (bp) Reference†
rs699947 Fw 5’-GCCTTAGGACACCATACCGATG-3’
Rv 5’-GCTGCCCCAGGGAACAAAGTTG-3’
PCR/RFLP
(Bgl II)
CC: 285
CA: 285,206,79
AA: 206,79
Modified from [3]
rs1570360 Fw 5’-TCCTGCTCCCTCCTCGCCAATG-3’
Rv 5’-GGCGGGGACAGGCGAGCATCAG-3’
PCR/RFLP
(Mnl I)
AA: 206
AG: 206,180,26
GG: 180,26
Modified from [19]
rs2010963 Fw 5’-CCGACGGCTTGGGGAGATTGCTC-3’
Rv 5’-CGGCGGTCACCCCCAAAAGCAG-3’
PCR/RFLP
(BsmF 1)
GG:157, 40
GC: 197,157,40
CC: 197
Modified from [3]
rs25648 —— Real time PCR Taqman assay —— hCV791476
*Nucleotides in bold letters in primer sequences indicate primer modifications included in this study. †Original references of primer sequences and protocols.
Table 2 Demographic variables and risk factors of the
study population
Characteristic Controls
(n = 78)
PE cases
(n = 86)
P
value
Maternal age, mean (range) years 25 (17-36) 27 (15-38) 0.067
Gestational age, median (range) weeks 32 (16-38) 34 (17-37) 0.028*
Number of pregnancies, median (range) 2 (1-6) 2 (1-5) 0.614
Family history of PE, n (%) 5 (6.4) 7 (8.1) 0.337
Family history of type 2 Diabetes
mellitus, n (%)
24 (30.76) 35 (40.7) 0.784
Family history of arterial hypertension,
n (%)
31 (39.74) 37 (43.02) 0.409
Primipaternity, n (%) 24 (30.76) 27 (28.13) 0.531
Use of barrier contraceptive method,
n (%)
29 (37.18) 28 (33.55) 0.392
Nulliparous, n (%) 28 (35.89) 35 (40.69) 0.995
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combinations of the VEGF variants, we performed a
haplotype analysis on for the four VEGF SNPs. A link-
age disequilibrium (LD) test, showed a LD association
between the rs699947, rs1570360, rs2010963, and
rs25648 VEGF variants (D’ > 0.87, range: 0.882 to
0.998 P <0 . 0 0 1 ) .T h ed a t af o rD ’statistic of each pair-
wise of SNPs and its p values are shown in table S2 of
Additional file 2. A comparison between haplotypes
frequencies of VEGF SNPs and their association with
PE is summarized in Table 4. Five major combina-
tions between VEGF SNPs studied were determined;
four of them with frequencies above 10% (C-G-C-C,
C-G-G-C, A-A-G-C, and A-G-G-T for rs699947,
rs1570360, rs2010963, and rs25648 VEGF SNPs,
respectively) and one of them, A-G-G-C, with a fre-
quency of 1.5%.
The P values for individual and global haplotype score
tests (Table 4) did not indicate a significant difference
in VEGF haplotype frequency profiles between cases and
controls (P > 0.05).
Considering the sample size of 164, the study power
was calculated in a range of 45.19% to 65.96% to detect
an effect of size 2 or greater depending on the SNP
considered.
Discussion
Genetic predisposition is a well-documented risk factors
for PE [21,22]; however, although several genes have
been postulated as genetic susceptibility markers of the
disease [21-24], there is not a recognized hereditary pro-
file to explain the association [21]. Considering differ-
ences in genetic predisposition between populations and
the important role of VEGF gene in the angiogenesis
during the pregnancy, we conducted a case-control
study, to test the association between the rs699947,
rs1570360, rs2010963, and rs25648 VEGF genetic var-
iants and PE. Consistent with the lack of association
between -2578C/A (rs699947) VEGF genotypic/allelic
frequencies in women with severe PE reported by Papa-
zoglou D et al (2004) in Greece [13], we did not find an
association between genotype/allele frequencies of the
studied SNPs and PE or with severity of the disease (P >
0.05). However, our results contrasted with those
reported by Sandrim VC et al. (2009) for Caucasic Bra-
zilian women, who reported a positive association
between -2578C/A (but not for -1154G/A) genotypes
and PE [12]. Banyasz I et al (2006) suggested that car-
riers of the VEGF+405G (rs2010963) allele in an Hun-
garian population have a decreased susceptibility to PE
and while carriers of the VEGF-2578A (rs699947) allele
could be associated with an accelerated development of
the disease in nulliparous pregnant women with severe
PE [3]. In our study, carriers of the VEGF+405G
(rs2010963) allele did not have a decreased susceptibility
to PE and no association was found between allele/gen-
otypes frequencies of the studied VEGF variants (includ-
ing VEGF-2578 C/A) and PE onset. Discrepancies of
VEGF allele/genotype frequencies and their association
with PE, severity, or onset of disease, may be explained
Table 3 Comparison of allele and genotype frequencies
between study groups
dbSNP
ID
Genotype
and minor
allele
Controls
(n = 78)
PE
Cases
(n = 86)
OR (CI 95%) P
value
rs699947 CC 35 (0.45) 29 (0.34) 0.75 (0.27-2.08) 0.31
CA 34 (0.44) 47 (0.55)
AA 9 (0.11) 10 (0.11)
Allele A 52 (0.33) 67 (0.39) 0.78 (0.49-1.23) 0.34
rs1570360 GG 49 (0.63) 51 (0.59) 0.94 (0.49-1.80) 0.57
GA 27 (0.35) 30 (0.35)
AA 2 (0.02) 5 (0.06)
Allele A 31 (0.2) 40 (0.23) 0.82 (0.48-1.38) 0.54
rs2010963 GG 26 (0.33) 28 (0.33) 1.03 (0.52-2.03) 0.79
GC 43 (0.55) 45 (0.52)
CC 9 (0.12) 13 (0.15)
Allele C 61 (0.39) 71 (0.41) 0.91 (0.58-1.42) 0.77
rs25648 CC 55 (0.70) 62 (0.72) 0.98 (0.49-1.98) 0.53
CT 20 (0.26) 23 (0.27)
TT 3 (0.04) 1 (0.01)
Allele T 26 (0.17) 25 (0.15) 1.17 (0.64-2.13) 0.70
Table 4 Analysis of haplotypes frequencies and their association with PE
SNP
Haplotype* rs699947 rs1570360 rs2010963 rs25648 Freq OR (95% CI) P value
1 C G C C 0.3851 1 -
2 C G G C 0.2308 1.31 (0.72-2.39) 0.38
3 A A G C 0.1953 0.72 (0.37-1.37) 0.31
4 A G G T 0.1358 0.92 (0.44-1.96) 0.84
5 A G G C 0.015 1.63 (0.33-8.13) 0.55
Global haplotype association p value 0.12
* The SNP order which defined the VEGF haplotype structure was rs699947, rs1570360, rs2010963, and rs25648, respectively.
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by differences in selection criteria of the studied groups.
For example, the lack of consensus in the controls selec-
tion, which has included post-menopausal women with
a history of at least two uncomplicated pregnancies, nul-
liparous pregnant women, women with uncomplicated
pregnancies, or normotensive pregnant women, makes
difficult the comparison between studies and may
include some bias in the association reports.
PE susceptibility related to VEGF haplotypes has
been considered in a very few studies; however, none
of them has genotyped all the variants included in this
work. We did not find differences in the identified
haplotypes profiles between cases and controls. In con-
trast with our results, Sandrim VC et al. (2009) sug-
gested a protective effect for the -2578C, -1154G and
-634C haplotype (associated with higher VEGF gene
expression) against the development of PE [12]. In our
study, we did not include the -634G/C variant; how-
ever, although we performed a statistical analyses in
which only the -2578C/A, -1154G/A SNPs were con-
sidered for this analysis, the lack of association
between VEGF haplotypes frequencies and PE was
consistent. Finally, some considerations should be
highlighted: One of the major limitations of this work
was the small sample size because it influenced the
study power (calculated in a range of 45.19% to 65.96%
depending on the SNP studied). In this same sense,
the limited sample size affects the association analyses
performed in sub-classified groups, as PE severity or
PE onset, since sub-classifications reduced the num-
bers of study subjects and could introduce some bias
in the statistical analysis. In our, study the nulliparous
state was not considered as selection criteria or was
subclassified for additional comparisons; however, this
PE risk factor showed no difference between groups.
Our control group included normotensive women, but
their “current healthy pregnant state” does not discard
t h ef u t u r ep r e s e n c eo fP Ep r e g n a n c i e s .
In Mexico, there are no data about genetic susceptibil-
ity for PE associated to VEGF variants. Our study is the
f i r s tp r o t o c o lt h a te v a l u a t ed the possible association
between VEGF genotypes/haplotypes and PE, and the
results obtained in the study suggest the presence of
additional genetic variants different from rs699947,
rs1570360, rs2010963, and rs25648 VEGF as markers for
the genetic susceptibility to PE.
Conclusion
In our study, there was no evidence of an association
between allele, genotype or haplotype frequencies and
PE, its severity or onset of the disease.
Additional material
Additional file 1: Comparison of alleles, genotypes, and haplotypes
frequencies between study groups, according to disease severity.
Additional file 2: Linkage Disequilibrium Analysis.D ’ statistics and P
values for each parwise of VEGF variants included in the study.
Acknowledgements
We thank all the study participants. Authors thank M. en C. Alfredo Salazar
de Santiago and Dra. Ma. del Carmen Aceves Medina from Area de Ciencias
de la Salud (Universidad Autonoma de Zacatecas) for their contributions and
support. This work was supported in part from FOMIX CONACyT-Gobierno
del Estado de Zacatecas Grant, (ID number: 121535).
Author details
1Laboratorio de Medicina Molecular, Unidad Academica de Medicina
Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas,
Carretera Zacatecas-Guadalajara Km.6. Ejido la Escondida, Zacatecas, Mexico.
2Unidad Medica Materno-Fetal del Noreste, Unidad Medica de Alta
Especialidad No. 23 Instituto Mexicano del Seguro Social, Avenida
Constitucion y Felix U. Gomez, Col. Centro, Monterrey, Mexico.
3Unidad
Academica de Enfermeria, Universidad Autonoma de Zacatecas, Carretera
Zacatecas-Guadalajara Km.6. Ejido la Escondida, Zacatecas, Mexico.
4Department of Biochemistry and Molecular Medicine, University Hospital
Universidad Autonoma de Nuevo Leon, Av. F. I. Madero S/N, Col. Mitras
Centro, Monterrey, Mexico.
5Centro de Investigacion y Desarrollo en Ciencias
de la Salud, Universidad Autonoma de Nuevo Leon, Calle Carlos Canseco S/
N, Col. Mitras Centro, Monterrey, Mexico.
Authors’ contributions
IGV and CCDLR carried out the samples processing and the molecular
genetic studies, IGV drafted the manuscript. RCF and VMG participated in
the design of the study and in the coordination of patient recruitment.
JERM, EAGM, and EML participated in data acquisition, analysis and
interpretation, and reviewed the manuscript. ARM and ROL were involved in
the design of the study and in the preparation of the manuscript. MLMF
conceived the study, participated in its design and coordination, performed
the statistical analysis, and helped to draft the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests. The authors are
responsible for the content and writing of the research paper.
Received: 18 January 2011 Accepted: 16 May 2011
Published: 16 May 2011
References
1. Sibai BM, Stella CL: Diagnosis and management of atypical preeclampsia-
eclampsia. Am J Obstet Gynecol 2009, 200(5):481.e1-481.e7.
2. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005,
365(9461):785-799.
3. Banyasz I, Szabo S, Bokodi G, Vannay A, Vasarhelyi B, Szabo A, Tulassay T,
Rigo J Jr: Genetic polymorphisms of vascular endothelial growth factor
in severe pre-eclampsia. Mol Hum Reprod 2006, 12(4):233-236.
4. (SINAIS) SNdIeS: Principales causas de mortalidad materna en México,
2005-2007. 2007 [http://sinais.salud.gob.mx/descargas/xls/
Princip_CausasMM_2005-2007.xls].
5. Geusens N, Verlohren S, Luyten C, Taube M, Hering L, Vercruysse L,
Hanssens M, Dudenhausen JW, Dechend R, Pijnenborg R: Endovascular
trophoblast invasion, spiral artery remodelling and uteroplacental
haemodynamics in a transgenic rat model of pre-eclampsia. Placenta
2008, 29(7):614-623.
6. Jauniaux E, Poston L, Burton GJ: Placental-related diseases of pregnancy:
Involvement of oxidative stress and implications in human evolution.
Hum Reprod Update 2006, 12(6):747-755.
Garza-Veloz et al. BMC Pregnancy and Childbirth 2011, 11:35
http://www.biomedcentral.com/1471-2393/11/35
Page 5 of 67. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK:
Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989,
161(5):1200-1204.
8. Li H, Gu B, Zhang Y, Lewis DF, Wang Y: Hypoxia-induced increase in
soluble Flt-1 production correlates with enhanced oxidative stress in
trophoblast cells from the human placenta. Placenta 2005, 26(2-
3):210-217.
9. Gu Y, Lewis DF, Wang Y: Placental productions and expressions of
soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and
placental growth factor in normal and preeclamptic pregnancies. J Clin
Endocrinol Metab 2008, 93(1):260-266.
10. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K,
Damsky C, Fisher SJ: Vascular endothelial growth factor ligands and
receptors that regulate human cytotrophoblast survival are dysregulated
in severe preeclampsia and hemolysis, elevated liver enzymes, and low
platelets syndrome. Am J Pathol 2002, 160(4):1405-1423.
11. Srinivas SK, Morrison AC, Andrela CM, Elovitz MA: Allelic variations in
angiogenic pathway genes are associated with preeclampsia. Am J
Obstet Gynecol 202(5):445-e441-411.
12. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G, Tanus-
Santos JE: Vascular endothelial growth factor genotypes and haplotypes
are associated with pre-eclampsia but not with gestational
hypertension. Mol Hum Reprod 2009, 15(2):115-120.
13. Papazoglou D, Galazios G, Koukourakis MI, Panagopoulos I,
Kontomanolis EN, Papatheodorou K, Maltezos E: Vascular endothelial
growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod
2004, 10(5):321-324.
14. Kim YJ, Park BH, Park H, Jung SC, Pang MG, Ryu HM, Lee KS, Eom SM,
Park HY: No association of the genetic polymorphisms of endothelial
nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and
vascular endothelial growth factor with preeclampsia in Korean
populations. Twin Res Hum Genet 2008, 11(1):77-83.
15. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The
classification and diagnosis of the hypertensive disorders of pregnancy:
statement from the International Society for the Study of Hypertension
in Pregnancy (ISSHP). Hypertens Pregnancy 2001, 20(1):IX-XIV.
16. ACOG practice bulletin. Diagnosis and management of preeclampsia
and eclampsia. Number 33, January 2002. Obstet Gynecol 2002,
99(1):159-167.
17. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV: Novel
polymorphisms in the promoter and 5’ UTR regions of the human
vascular endothelial growth factor gene. Hum Immunol 1999,
60(12):1245-1249.
18. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J,
Figg WD: The role of vascular endothelial growth factor SNPs as
predictive and prognostic markers for major solid tumors. Mol Cancer
Ther 2009, 8(9):2496-2508.
19. Liu Q, Li Y, Zhao J, Sun DL, Duan YN, Wang N, Zhou RM, Kang S:
Association of polymorphisms -1154G/A and -2578C/A in the vascular
endothelial growth factor gene with decreased risk of endometriosis in
Chinese women. Hum Reprod 2009, 24(10):2660-2666.
20. Gauderman W, Morrison J: QUANTO 1.1: A computer program for power
and sample size calculations for genetic-epidemiology studies. 2006
[http://hydra.usc.edu/gxe/].
21. Chappell S: Searching for genetic clues to the causes of pre-eclampsia.
Clinical science (London, England: 1979) 2006, 110(4):443-458.
22. Goddard KA, Tromp G, Romero R, Olson JM, Lu Q, Xu Z, Parimi N, Nien JK,
Gomez R, Behnke E, Solari M, Espinoza J, Santolaya J, Chaiworapongsa T,
Lenk GM, Volkenant K, Anant MK, Salisbury BA, Carr J, Lee MS, Vovis GF,
Kuivaniemi H: Candidate-gene association study of mothers with pre-
eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum
Hered 2007, 63(1):1-16.
23. Bombell S, McGuire W: Tumour necrosis factor (-308A) polymorphism in
pre-eclampsia: meta-analysis of 16 case-control studies. Aust N Z J Obstet
Gynaecol 2008, 48(6):547-551.
24. Dissanayake VH, Giles V, Jayasekara RW, Seneviratne HR, Kalsheker N,
Broughton Pipkin F, Morgan L: A study of three candidate genes for pre-
eclampsia in a Sinhalese population from Sri Lanka. J Obstet Gynaecol Res
2009, 35(2):234-242.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2393/11/35/prepub
doi:10.1186/1471-2393-11-35
Cite this article as: Garza-Veloz et al.: No association between
polymorphisms/haplotypes of the vascular endothelial growth factor
gene and preeclampsia. BMC Pregnancy and Childbirth 2011 11:35.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Garza-Veloz et al. BMC Pregnancy and Childbirth 2011, 11:35
http://www.biomedcentral.com/1471-2393/11/35
Page 6 of 6